[1]
|
Turesson, I., Bjorkholm, M., Blimark, C.H., Kristinsson, S., Velez, R. and Landgren, O. (2018) Rapidly Changing My-eloma Epidemiology in the General Population: Increased Incidence, Older Patients, and Longer Survival. European Journal of Haematology. https://doi.org/10.1111/ejh.13083
|
[2]
|
Ramasamy, K., Gay, F., Weisel, K., Zweegman, S., Mateos, M.V. and Richardson, P. (2021) Improving Outcomes for Patients with Relapsed Multiple Myeloma: Chal-lenges and Considerations of Current and Emerging Treatment Options. Blood Reviews, 49, Article ID: 100808. https://doi.org/10.1016/j.blre.2021.100808
|
[3]
|
Touzeau, C., Moreau, P. and Dumontet, C. (2017) Monoclonal Antibody Therapy in Multiple Myeloma. Leukemia, 31, 1039-1047. https://doi.org/10.1038/leu.2017.60
|
[4]
|
Vaxman, I., Sidiqi, M.H. and Gertz, M. (2018) Venetoclax for the Treat-ment of Multiple Myeloma. Expert Review of Hematology, 11, 915-920. https://doi.org/10.1080/17474086.2018.1548931
|
[5]
|
Wu, H., Zhang, H., He, H.Y., et al. (2017) Cytogenetic Ab-normalities and Prognosis of 532 Patients with Multiple Myeloma. The Journal Covers All Aspects of Hematology, 38, 739-743.
|
[6]
|
Wong, K.Y. and Chim, C.S. (2020) Venetoclax, Bortezomib and S63845, an MCL1 Inhibitor, in Multiple Myeloma. Journal of Pharmacy and Pharmacology, 72, 728-737. https://doi.org/10.1111/jphp.13240
|
[7]
|
Basali, D., Chakraborty, R., Rybicki, L., et al. (2020) Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t(11;14) Multiple Myeloma. British Journal of Haematology, 189, 1136-1140.
https://doi.org/10.1111/bjh.16454
|
[8]
|
Costa, L.J., Davies, F.E., Monohan, G.P., et al. (2021) Phase 2 Study of Venetoclax plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood Ad-vances, 5, 3748-3759.
https://doi.org/10.1182/bloodadvances.2020004146
|
[9]
|
Ashkenazi, A., Fairbrother, W.J., Leverson, J.D. and Souers, A.J. (2017) From Basic Apoptosis Discoveries to Advanced Selective BCL-2 Family Inhibitors. Nature Reviews Drug Discovery, 16, 273-284.
https://doi.org/10.1038/nrd.2016.253
|
[10]
|
Kumar, S., Kaufman, J.L., Gasparetto, C., et al. (2017) Efficacy of Ve-netoclax as Targeted Therapy for Relapsed/ Refractory t(11;14) Multiple Myeloma. Blood, 130, 2401-2409. https://doi.org/10.1182/blood-2017-06-788786
|
[11]
|
Maples, K.T., Nooka, A.K., Gupta, V., et al. (2021) Natural History of Multiple Myeloma Patients Refractory to Venetoclax: A Single Center Experience. The American Journal of Hematology, 96, E68-E71.
https://doi.org/10.1002/ajh.26064
|
[12]
|
Nahi, H., Kashif, M., Klimkowska, M., et al. (2021) Low Dose Venetoclax as a Single Agent Treatment of Plasma Cell Malignancies Harboring t(11;14). The American Journal of Hematology, 96, 925-933.
https://doi.org/10.1002/ajh.26207
|
[13]
|
Seymour, J.F., Kipps, T.J., Eichhorst, B., et al. (2018) Veneto-clax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. The New England Journal of Medicine, 378, 1107-1120. https://doi.org/10.1056/NEJMoa1713976
|
[14]
|
Di Nardo, C.D., Pratz, K., Pullarkat, V., et al. (2019) Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia. Blood, 133, 7-17.
https://doi.org/10.1182/blood-2018-08-868752
|
[15]
|
Wei, A.H., Strickland, S.A., Hou, J.Z., et al. (2019) Veneto-clax Combined with Low-Dose Cytarabine for Previously Untreated Patients with Acute Myeloid Leukemia: Results from a Phase Ib/II Study. Journal of Clinical Oncology, 37, 1277-1284. https://doi.org/10.1200/JCO.18.01600
|
[16]
|
Green, D.R. and Llambi, F. (2015) Cell Death Signaling. Cold Spring Harbor Perspectives in Biology, 7, a006080.
https://doi.org/10.1101/cshperspect.a006080
|
[17]
|
Kale, J., Osterlund, E.J. and Andrews, D.W. (2018) BCL-2 Fam-ily Proteins: Changing Partners in the Dance towards Death. Cell Death & Differentiation, 25, 65-80. https://doi.org/10.1038/cdd.2017.186
|
[18]
|
Moreau, P., Chanan-Khan, A., Roberts, A.W., et al. (2017) Promising Efficacy and Acceptable Safety of Venetoclax plus Bortezomib and Dexamethasone in Relapsed/Refractory MM. Blood, 130, 2392-2400.
https://doi.org/10.1182/blood-2017-06-788323
|
[19]
|
Matulis, S.M., Gupta, V.A., Nooka, A.K., et al. (2016) Dex-amethasone Treatment Promotes Bcl-2 Dependence in Multiple Myeloma Resulting in Sensitivity to Venetoclax. Leuke-mia, 30, 1086-1093.
https://doi.org/10.1038/leu.2015.350
|
[20]
|
Touzeau, C., Dousset, C., Le Gouill, S., et al. (2014) The Bcl-2 Specific BH3 Mimetic ABT-199: A Promising Targeted Therapy for t(11;14) Multiple Myeloma. Leukemia, 28, 210-212. https://doi.org/10.1038/leu.2013.216
|
[21]
|
Touzeau, C., Le Gouill, S., Mahé, B., et al. (2017) Deep and Sustained Response after Venetoclax Therapy in a Patient with Very Advanced Refractory Myeloma with Translocation t(11;14). Haematologica, 102, e112-e114.
https://doi.org/10.3324/haematol.2016.160408
|
[22]
|
Kambhampati, S., Galligan, D., Huang, C.Y., et al. (2020) A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma. Leukemia & Lymphoma, 61, 1211-1219.
https://doi.org/10.1080/10428194.2019.1709835
|
[23]
|
Roberts, A.W., Davids, M.S., Pagel, J.M., et al. (2016) Tar-geting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. The New England Journal of Medicine, 374, 311-322. https://doi.org/10.1056/NEJMoa1513257
|
[24]
|
Jelinek, T., Popkova, T., Duras, J., et al. (2020) Veneto-clax plus Bortezomib and Dexamethasone in Heavily Pretreated End-Stage Myeloma Patients without t(11;14): A Re-al-World Cohort. Hematological Oncology, 38, 412-414.
https://doi.org/10.1002/hon.2736
|
[25]
|
Kumar, S.K., Harrison, S.J., Cavo, M., et al. (2020) Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 21, 1630-1642. https://doi.org/10.1016/S1470-2045(20)30525-8
|
[26]
|
Boccon-Gibod, C., Talbot, A., Le Bras, F., et al. (2020) Car-filzomib, Venetoclax and Dexamethasone for Relapsed/ Refractory Multiple Myeloma. British Journal of Haematology, 189, e73-e76. https://doi.org/10.1111/bjh.16483
|
[27]
|
Bahlis, N.J., Baz, R., Harrison, S.J., et al. (2021) Phase I Study of Venetoclax plus Daratumumab and Dexamethasone, with or without Bortezomib, in Patients with Relapsed or Refractory Multiple Myeloma with and without t(11;14). Journal of Clinical Oncology, 39, 3602-3612. https://doi.org/10.1200/JCO.21.00443
|
[28]
|
Sidiqi, M.H., Al Saleh, A.S., Kumar, S.K., et al. (2021) Venetoclax for the Treatment of Multiple Myeloma: Outcomes Outside of Clinical Trials. The American Journal of Hematology, 96, 1131-1136. https://doi.org/10.1002/ajh.26269
|
[29]
|
Seymour, J.F., Ma, S., Brander, D.M., et al. (2017) Venetoclax plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukaemia: A Phase 1b Study. The Lancet Oncology, 18, 230-240.
https://doi.org/10.1016/S1470-2045(17)30012-8
|
[30]
|
Coiffier, B., Altman, A., Pui, C.H., Younes, A. and Cairo, M.S. (2008) Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Re-view. Journal of Clinical Oncology, 26, 2767-2778.
https://doi.org/10.1200/JCO.2007.15.0177
|
[31]
|
Motoyama, N., Kimura, T., Takahashi, T., Watanabe, T. and Nakano, T. (1999) Bcl-x Prevents Apoptotic Cell Death of both Primitive and Definitive Erythrocytes at the End of Mat-uration. Journal of Experimental Medicine, 189, 1691-1698. https://doi.org/10.1084/jem.189.11.1691
|
[32]
|
Zhang, H., Nimmer, P.M., Tahir, S.K., et al. (2007) Bcl-2 Family Proteins Are Essential for Platelet Survival. Cell Death & Dif-ferentiation, 14, 943-951. https://doi.org/10.1038/sj.cdd.4402081
|